BUB1B

Mitotic checkpoint serine/threonine-protein kinase BUB1 beta

1,985 patent compounds predicted against BUB1B, 1,847 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL265061	1.00	1/20
Ceritinib (SCHEMBL1014329)	1.00	1/20
Ceritinib (SCHEMBL9936675)	0.98	1/20
SCHEMBL1545837	0.94	1/20
SCHEMBL1014579	0.89	1/20
SCHEMBL12224983	0.86	1/20
SCHEMBL271198	0.85	1/20
SCHEMBL263665	0.84	1/20
SCHEMBL1545350	0.84	1/20
SCHEMBL1545942	0.84	1/20
SCHEMBL270925	0.83	1/20
SCHEMBL263679	0.83	1/20
SCHEMBL265965	0.82	1/20
SCHEMBL1545695	0.82	1/20
SCHEMBL1545696	0.82	1/20
SCHEMBL1546327	0.82	1/20
SCHEMBL12213859	0.82	1/20
SCHEMBL270528	0.82	1/20
SCHEMBL266295	0.82	1/20
SCHEMBL12237713	0.82	1/20

Germline variants in BUB1B on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full BUB1B gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to BUB1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression	PHASE3	RECRUITING
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer	PHASE2	UNKNOWN
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer	PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects	PHASE1/PHASE2	COMPLETED
Abemaciclib With or Without Atezolizumab for mCRPC	PHASE2	COMPLETED
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)	PHASE1/PHASE2	RECRUITING
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	PHASE1/PHASE2	COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer	PHASE1	COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Clinical Study of TQB3824 in Subjects With Advanced Cancer	PHASE1	UNKNOWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	WITHDRAWN
Tabectedin to Treat Children and Adolescents With Cancer	PHASE1	COMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer	nan	COMPLETED
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a BUB1B binder may also engage these)

Protein	Name	Similarity
Q9Z1S0	—	0.998	Q9Z1S0 →
Q8BMD7	—	0.995	Q8BMD7 →
O08901	—	0.995	O08901 →
O22806	—	0.992	O22806 →
PIK3C2A	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	0.991	landscape →
Q9C0F1	—	0.991	Q9C0F1 →
Q5R789	—	0.990	Q5R789 →
Q1LYM3	—	0.990	Q1LYM3 →
Q6DGB6	—	0.990	Q6DGB6 →
Q6DD45	—	0.990	Q6DD45 →
O59767	—	0.990	O59767 →
Q8TDB6	—	0.990	Q8TDB6 →
Q9FY74	—	0.990	Q9FY74 →
Q9DDT2	—	0.990	Q9DDT2 →
Q9NQW6	—	0.990	Q9NQW6 →
Q6IVY4	—	0.990	Q6IVY4 →
Q7T0S7	—	0.989	Q7T0S7 →
Q9LSP8	—	0.989	Q9LSP8 →
Q28E45	—	0.989	Q28E45 →
P58501	—	0.989	P58501 →
Q8NHQ8	—	0.989	Q8NHQ8 →
P35611	—	0.988	P35611 →
A1A4J7	—	0.988	A1A4J7 →
Q8BX57	—	0.988	Q8BX57 →
Q9LZZ7	—	0.988	Q9LZZ7 →
Q3T9Z9	—	0.988	Q3T9Z9 →
Q6NRK1	—	0.988	Q6NRK1 →
Q9CYA6	—	0.988	Q9CYA6 →
Q9Y2H2	—	0.988	Q9Y2H2 →
A8E7C5	—	0.988	A8E7C5 →